Chinese drugmaker HEC Pharm Co shot back Wednesday at a request by Novartis Pharmaceuticals Corp to block generic versions of Novartis’ blockbuster multiple-sclerosis drug Gilenya while the U.S. Supreme Court weighs whether to hear the companies’ patent dispute.